Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
RemeGen Co. Ltd. Class H ( (HK:9995) ) has issued an update.
RemeGen Co., Ltd. held its 2025 second class meeting of H shareholders, where key resolutions were passed, including changes to the company’s registered capital and amendments to its Articles of Association. The meeting saw participation from shareholders representing approximately 19.67% of the total issued H shares, with all resolutions receiving the required majority vote, indicating strong shareholder support for the proposed changes.
The most recent analyst rating on (HK:9995) stock is a Buy with a HK$19.59 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating within the pharmaceutical industry. The company focuses on the development and commercialization of innovative biologic drugs, particularly targeting oncology and autoimmune diseases.
Average Trading Volume: 11,694,103
Technical Sentiment Signal: Buy
Current Market Cap: HK$41.36B
For detailed information about 9995 stock, go to TipRanks’ Stock Analysis page.